Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation…
Read More
Follow-Up Supports MammaPrint to Guide Chemo Decisions, Points to an ‘Age Effect’
NEW YORK (Reuters Health) – Longer-term follow-up data from the MINDACT trial confirm the clinical utility of the 70-gene MammaPrint assay to help guide chemotherapy decisions in women with early breast cancer, but also suggests that age may be a…
Read More
EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma
European Union approval has been recommended for duvelisib (Copiktra) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or refractory follicular lymphoma (FL) who have received at least two prior lines of therapy. The European Medicines Agency’s Committee for Medicinal Products…
Read More
Could Tamoxifen Dose Be Slashed Down to 2.5 mg?
Tamoxifen has long been used in breast cancer, both in the adjuvant and preventive setting, but uptake and adherence are notoriously low, mainly because of adverse events. Using a much lower dose to reduce the incidence of side effects would…
Read More
Phase 3 DREAM3R trial opens for malignant pleural mesothelioma
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials,…
Read More
New inhibitor makes drug-resistant tumor cells respond again to chemotherapy
A new substance could improve the treatment of persistent cancers. Researchers at Martin Luther University Halle-Wittenberg (MLU) and the University of Greifswald have developed a new inhibitor that makes drug-resistant tumor cells respond again to chemotherapy. The new substance blocks…
Read More
New ASH Guidelines: VTE Prevention, Treatment in Cancer Patients
New guidelines from the American Society of Hematology “strongly recommend” using no thromboprophylaxis over using parenteral thromboprophylaxis in ambulatory patients receiving cancer chemotherapy who have low venous thromboembolism (VTE) risk, and using no thromboprophylaxis over oral thromboprophylaxis with vitamin K…
Read More
FDA-approved antidiarrhea drug can reverse resistance to chemotherapy in a mouse model of leukemia
New research into one of the most common and difficult cancers to treat has revealed an effective route to mitigating chemotherapy resistance through the use of a drug already approved by the FDA to treat diarrhea. The findings are published…
Read More
Xenograft model for invasive lobular carcinoma simulates tumor with high accuracy
Invasive lobular carcinoma (ILC) is a type of breast cancer that begins in the milk-producing glands (lobules) of the breast. It covers 10-15% of all breast cancer cases, has a high risk of late recurrence, unique metastatic sites, high sensitivity…
Read More
Aprepitant APOTEX
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. APREPITANT APOTEX aprepitant Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about this medicine. It does not contain all the available…
Read More